Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04767373 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
A Phase 2 study of Respiratory Syncytial Virus Infection, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 3,632
- Enrollment target
- 20
- Study locations
NCT04767373: Completed Phase 2 study of Respiratory Syncytial Virus Infection, sponsored by Merck Sharp & Dohme.
NCT04767373 is a Phase 2 study of Respiratory Syncytial Virus Infection that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 3,632 participants, above the 100-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (3532% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04767373, a Phase 2 study of Respiratory Syncytial Virus Infection, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3,632 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated medically attended lower respiratory infection (MALRI) from Days 1 through 150 postdose compared to placebo.
Primary Outcome
Outpatient and inpatient MALRI was defined as the presence of the following in a clinical setting: 1) cough or difficulty breathing; AND 2) 1 or more of wheezing, chest wall in-drawing/retraction, rales/crackles, hypoxemia, tachypnea, or dehydration due to respiratory symptoms; AND 3) RSV-positive reverse transcriptase polymerase chain reaction (RT-PCR) nasopharyngeal sample. Per protocol, the participants with outpatient and inpatient RSV-associated MALRI were reported together for RSV season 1
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Clesrovimab
Study Locations (20)
California
- Long Beach Memorial Medical Center ( Site 0014) - Long Beach
- Madera Family Medical Group ( Site 0046) - Madera
- Orange County Research Institute ( Site 0057) - Ontario
Arkansas
- Northwest Arkansas Pediatric Clinic ( Site 0050) - Fayetteville
- Children's Clinic of Jonesboro, PA ( Site 0058) - Jonesboro
Colorado
- Children's Hospital Colorado ( Site 0066) - Aurora
- Optumcare Colorado Springs, LLC ( Site 0022) - Colorado Springs
District of Columbia
- Children's National Hospital ( Site 0076) - Washington D.C.
- MedStar Georgetown Pediatrics ( Site 0047) - Washington D.C.
Florida
- Next Phase Research Alliance, LLC ( Site 0071) - Homestead
- Acevedo Clinical Research Associates ( Site 0002) - Miami
Georgia
- Tekton Research ( Site 0080) - Chamblee
- Meridian Clinical Research, LLC ( Site 0083) - Macon
Idaho
- Clinical Research Prime ( Site 0075) - Idaho Falls
- Saltzer Medical Group ( Site 0004) - Nampa
Nebraska
- Meridian Clinical Research, LLC ( Site 0082) - Hastings
- Midwest Children's Health Research Institute, LLC ( Site 0044) - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,632 participants |
| Start Date | 2021-04-07 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 2 |
What the finished NCT04767373 record still lists
NCT04767373 is an interventional study that assigns participants to a tested intervention. Its 3,632 participants enrollment target places it among the larger protocols in the corpus, above the 100-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (3532% higher).
The record links to 1 condition, with Respiratory Syncytial Virus Infection appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04767373 names 20 study sites across 11 states, led by California, Arkansas, Colorado.
Frequently Asked Questions
What is clinical trial NCT04767373 about?
NCT04767373 is a clinical study titled "Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)". The primary objectives of this phase 2b/3 double-blind, randomized, placebo-controlled study are to evaluate the efficacy and safety of clesrovimab in healthy pre-term and full-term infants. It is hypothesized that clesrovimab will reduce the incidence of respiratory syncytial virus (RSV)-associated...
What is the current status of trial NCT04767373?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3,632 participants. The study started on 2021-04-07. Estimated completion is 2024-07-09.
What conditions does trial NCT04767373 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infection.
What interventions are being tested in trial NCT04767373?
The interventions under investigation include: Placebo (DRUG), Clesrovimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04767373?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04767373 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
COMPLETED · Phase 2
-
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
ACTIVE NOT RECRUITING · Phase 4
-
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06354920 · 3,624 participants · NA
M-Well Bonding Bundle to Improve Patient-Physician Relationships
- NCT06702553 · 3,650 participants · Phase 3
Nitric Oxide for Reduced Intensive Support in Cardiac Surgery With Cardiopulmonary Bypass
- NCT07249398 · 3,650 participants · NA
Influence of Social Media Ads on Food Choice - Master Protocol
- NCT06088498 · 3,600 participants · Phase 2
App for Reducing Cravings to Smoke
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI